|
|
|
| Research progress of the correlation between paclitaxel resistance mechanism for treating ovarian cancer and TLR4/MyD88 signaling pathway |
| The Second Hospital of Tianjin Medical University, Tianjin, 300211 |
|
|
|
|
Abstract Ovarian cancer is one of the most common cancers that cause death of women. It is a heterogeneous disease with complex molecular and genetic changes. The recurrence rate of ovarian cancer is relatively high, so it is important to understand the related mechanisms of drug resistance and to base on the specific changes of the tumor to target therapy more rationally. The Toll-like receptor TLR4 is expressed not only in immune cell, but also in tumor cells, especially in ovarian cancer cells. MyD88 has also recently been shown to promote both spontaneous and carcinogenic (propoxymethane) tumorigenesis. Paclitaxel is one of the important drugs for the treatment of ovarian cancer. As a major ligand of TLR4, paclitaxel activates the TLR4/MyD88 signaling pathway, and plays an important role in the proliferation and apoptosis of cancer cells. This paper mainly reviewed the research progress of the correlation between paclitaxel resistance for ovarian cancer and TLR4/MyD88 signaling pathway, in order to provide reference for clinical diagnosis and treatment.
|
|
|
|
|
|
|
|
|
